ESR1 and breast cancer: In addition, in ER+ breast cancer, tumors with low LN dissemination had higher ER levels, as compared to tumors with high LN dissemination (1.8-fold in LN ≤3 and 1.5-fold in LN−, compared to LN >3 and LN+, respectively); not surprisingly, patients with less LN-disseminated tumors have higher survival rate (Supplementary Fig. 1c, d).